Insider Trading Alert - MDVN, ACOR, MDT, UHS And CTSH Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 4, 2013, 189 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $160.56 to $35,901,027,172.20.

Highlighted Stocks Traded by Insiders:

Medivation (MDVN) - FREE Research Report

Hung David who is President and CEO at Medivation sold 15,050 shares at $62.61 on Dec. 4, 2013. Following this transaction, the President and CEO owned 950,204 shares meaning that the stake was reduced by 1.56% with the 15,050-share transaction.

Machado Clarence Patrick who is Chief Business Officer and CFO at Medivation sold 5,425 shares at $62.66 on Dec. 4, 2013. Following this transaction, the Chief Business Officer and CFO owned 30,830 shares meaning that the stake was reduced by 14.96% with the 5,425-share transaction.

The shares most recently traded at $61.70, down $0.96, or 1.55% since the insider transaction. Historical insider transactions for Medivation go as follows:

  • 24-Week # shares sold: 30,885

The average volume for Medivation has been 1.3 million shares per day over the past 30 days. Medivation has a market cap of $4.7 billion and is part of the health care sector and drugs industry. Shares are up 22.4% year-to-date as of the close of trading on Wednesday.

Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. Currently there are 10 analysts that rate Medivation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDVN - FREE

TheStreet Quant Ratings rates Medivation as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally high debt management risk. Get the full Medivation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Acorda Therapeutics (ACOR) - FREE Research Report

Cohen Ron who is President and CEO at Acorda Therapeutics sold 18,125 shares at $33.52 on Dec. 4, 2013. Following this transaction, the President and CEO owned 460,743 shares meaning that the stake was reduced by 3.78% with the 18,125-share transaction.

Blight Andrew who is Chief Scientifc Officer at Acorda Therapeutics sold 9,088 shares at $33.51 on Dec. 4, 2013. Following this transaction, the Chief Scientifc Officer owned 59,787 shares meaning that the stake was reduced by 13.19% with the 9,088-share transaction.

Wasman Jane who is President, Intl and GC at Acorda Therapeutics sold 8,425 shares at $33.52 on Dec. 4, 2013. Following this transaction, the President, Intl and GC owned 97,034 shares meaning that the stake was reduced by 7.99% with the 8,425-share transaction.

Sabella Lauren M who is Exec. VP-Commercial Dvlpmnt at Acorda Therapeutics sold 6,603 shares at $33.52 on Dec. 4, 2013. Following this transaction, the Exec. VP-Commercial Dvlpmnt owned 21,200 shares meaning that the stake was reduced by 23.75% with the 6,603-share transaction.

Lawrence David who is Chief of Business Operations at Acorda Therapeutics sold 10,836 shares at $33.51 on Dec. 4, 2013. Following this transaction, the Chief of Business Operations owned 14,194 shares meaning that the stake was reduced by 43.29% with the 10,836-share transaction.

Carrazana Enrique J. who is Chief Medical Officer at Acorda Therapeutics sold 1,640 shares at $33.56 on Dec. 4, 2013. Following this transaction, the Chief Medical Officer owned 32,527 shares meaning that the stake was reduced by 4.8% with the 1,640-share transaction.

The shares most recently traded at $32.05, down $1.51, or 4.7% since the insider transaction. Historical insider transactions for Acorda Therapeutics go as follows:

  • 4-Week # shares sold: 10,949
  • 12-Week # shares sold: 18,032
  • 24-Week # shares sold: 18,032

The average volume for Acorda Therapeutics has been 339,100 shares per day over the past 30 days. Acorda Therapeutics has a market cap of $1.4 billion and is part of the health care sector and drugs industry. Shares are up 35.6% year-to-date as of the close of trading on Wednesday.

Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. The company has a P/E ratio of 9.5. Currently there are 3 analysts that rate Acorda Therapeutics a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACOR - FREE

TheStreet Quant Ratings rates Acorda Therapeutics as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Acorda Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Medtronic (MDT) - FREE Research Report

Ayotte Neil P who is VP Interim Gen Counsel CorpSec at Medtronic sold 1,729 shares at $57.14 on Dec. 4, 2013. Following this transaction, the VP Interim Gen Counsel CorpSec owned 10,850 shares meaning that the stake was reduced by 13.74% with the 1,729-share transaction.

The shares most recently traded at $56.88, down $0.26, or 0.46% since the insider transaction. Historical insider transactions for Medtronic go as follows:

  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 66,491

The average volume for Medtronic has been 3.8 million shares per day over the past 30 days. Medtronic has a market cap of $57.5 billion and is part of the health care sector and health services industry. Shares are up 38.79% year-to-date as of the close of trading on Wednesday.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company operates in two segments, Cardiac and Vascular Group, and Restorative Therapies Group. The stock currently has a dividend yield of 1.94%. The company has a P/E ratio of 15.4. Currently there are 6 analysts that rate Medtronic a buy, no analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDT - FREE

TheStreet Quant Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, increase in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Medtronic Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Universal Health Services (UHS) - FREE Research Report

Hotz Robert H who is Director at Universal Health Services sold 20,000 shares at $82.58 on Dec. 4, 2013. Following this transaction, the Director owned 54,861 shares meaning that the stake was reduced by 26.72% with the 20,000-share transaction.

The shares most recently traded at $82.11, down $0.47, or 0.57% since the insider transaction. Historical insider transactions for Universal Health Services go as follows:

  • 12-Week # shares sold: 12,500
  • 24-Week # shares sold: 12,500

The average volume for Universal Health Services has been 705,500 shares per day over the past 30 days. Universal Health Services has a market cap of $7.6 billion and is part of the health care sector and health services industry. Shares are up 71.27% year-to-date as of the close of trading on Wednesday.

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The stock currently has a dividend yield of 0.24%. The company has a P/E ratio of 15.8. Currently there are 10 analysts that rate Universal Health Services a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UHS - FREE

TheStreet Quant Ratings rates Universal Health Services as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Universal Health Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cognizant Technology Solutions Corporation (CTSH) - FREE Research Report

Coburn Gordon who is President at Cognizant Technology Solutions Corporation sold 22,919 shares at $93.52 on Dec. 4, 2013. Following this transaction, the President owned 56,858 shares meaning that the stake was reduced by 28.73% with the 22,919-share transaction.

The shares most recently traded at $93.89, up $0.37, or 0.39% since the insider transaction. Historical insider transactions for Cognizant Technology Solutions Corporation go as follows:

  • 4-Week # shares sold: 653
  • 12-Week # shares sold: 28,226
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 122,015

The average volume for Cognizant Technology Solutions Corporation has been 2.0 million shares per day over the past 30 days. Cognizant Technology Solutions Corporation has a market cap of $28.4 billion and is part of the technology sector and computer software & services industry. Shares are up 26.35% year-to-date as of the close of trading on Wednesday.

Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process outsourcing services worldwide. The company operates through four segments: Financial Services; Healthcare; Manufacturing, Retail, and Logistics; and Other. The company has a P/E ratio of 24.1. Currently there are 14 analysts that rate Cognizant Technology Solutions Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTSH - FREE

TheStreet Quant Ratings rates Cognizant Technology Solutions Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Cognizant Technology Solutions Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs